The company’s market is disease management and in the current Salmonella/E-Coli environment it has strong potential for growth. Ranked at #60 in the Forbes list it has a 42% growth rate; a P/E Ratio of 23.08 and an EPS of $1.32 per share. It is currently trading off its projected 1 yr. target of $40.00 per share and is a premium at a discounted $30.39 per share. A covered call investing position for HWAY with August expiration currently has a potential return of 2.6% with 13.2% downside protection.
Analysts'
Recommendation: | Buy |
| 30 Days Ago: | Buy |
|
| Analysts' Target: | $43 |
| Analysts' Targets |
| BWS Financial | $40 |
| Hold |
Wednesday, March 19, 2008
|
| BWS Financial | $40 |
| Hold |
Wednesday, March 19, 2008
|
| Broadpoint Capital | $42 |
| Buy |
Monday, March 03, 2008
|
| Dougherty & Co. | $50 |
| Buy |
Wednesday, February 27, 2008
|
| Lehman Brothers | $36 |
| Equal-weight |
Wednesday, February 27, 2008
|
| Friedman, Billings, Ramsey & C | $45 |
| Outperform |
Tuesday, February 26, 2008
|
$26.83 (08/09/08)
